Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Bremen – page 6

121 clinical trials in Bremen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bremen at a glance
121
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

121 trials in Bremen

Open in trial search

Ewing's sarcoma

Recruiting

Study on Ewing Sarcoma Treatment with Vinorelbine and Drug Combination for Patients with Primary and Disseminated Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:GPOH gGmbH

Malignant melanoma

Recruiting

Study to Compare Fianlimab and Cemiplimab Combination with Pembrolizumab in Patients with High-Risk Melanoma After Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Acute lymphocytic leukaemia

Recruiting

Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Karolinska University Hospital

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Peripheral arterial occlusive disease

Not yet recruiting

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Squamous cell carcinoma of lung+3

Not yet recruiting

Tislelizumab with drug combination in patients with PD-L1‑high metastatic non‑small cell lung cancer and high tumor burden

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AIO-Studien gGmbH

Hodgkin's disease

Not yet recruiting

Phase II Study of Brentuximab Vedotin with Drug Combination in HIV‑Positive Patients with Advanced‑Stage Classic Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:University Of Cologne

Colorectal cancer metastatic

Not yet recruiting

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Acute myeloid leukaemia+1

Not yet recruiting

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:GPOH gGmbH

Dementia Alzheimer's type

Not yet recruiting

Study on JNJ-64042056 for Preclinical Alzheimer's Disease in Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-64042056
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Bremen

What the registry says about research in the country

01 Oncology - Blood Cancers

Groundbreaking research focusing on Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia, investigating novel combination therapies and treatment approaches for patients ineligible for intensive chemotherapy.

  • Novel drug combinations for AML treatment
  • Gene-specific targeted therapies
  • Pediatric lymphoma treatments
02 Breast Cancer Research

Comprehensive studies examining various types of breast cancer treatments, with particular focus on triple-negative and HR+/HER2- breast cancers. Research includes evaluation of immunotherapy and targeted therapeutic approaches.

  • Triple-negative breast cancer therapy
  • Endocrine therapy optimization
  • Metastatic disease management
03 Cardiovascular Studies

Innovative research targeting atherosclerotic cardiovascular disease and hypertension, exploring new treatment methods including cholesterol management and blood pressure control techniques.

  • Lipid-lowering therapies
  • Hypertension management
  • Cardiovascular risk reduction
Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.